Detalhe da pesquisa
1.
BCR::ABL1 Kinase N-lobe Mutants Confer Moderate to High Degrees of Resistance to Asciminib.
Blood
; 2024 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38643492
2.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 22(1): 43-69, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394770
3.
N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants.
Bioorg Chem
; 143: 106966, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37995643
4.
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Br J Haematol
; 202(5): 942-952, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246588
5.
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia.
Haematologica
; 107(11): 2641-2649, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511672
6.
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
Am J Hematol
; 97(11): 1419-1426, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054756
7.
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
Haematologica
; 106(4): 1034-1046, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414851
8.
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
Blood
; 132(4): 393-404, 2018 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567798
9.
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(10): 1385-1415, 2020 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33022644
10.
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.
Blood
; 130(1): 48-58, 2017 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28490572
11.
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.
Haematologica
; 104(1): 93-101, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30093398
12.
NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
J Natl Compr Canc Netw
; 17(5.5): 611-613, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31117031
13.
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 19(7): 889-903, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29859851
14.
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Blood
; 127(6): 703-12, 2016 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26603839
15.
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
BMC Cancer
; 18(1): 359, 2018 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29609532
16.
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 16(9): 1108-1135, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181422
17.
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
Nature
; 485(7397): 260-3, 2012 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22504184
18.
Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.
Ann Hematol
; 96(8): 1303-1313, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28534184
19.
Crenolanib is a selective type I pan-FLT3 inhibitor.
Proc Natl Acad Sci U S A
; 111(14): 5319-24, 2014 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24623852
20.
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 17(5): 612-21, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27083332